vs
Side-by-side financial comparison of Iridium Communications Inc. (IRDM) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Iridium Communications Inc. is the larger business by last-quarter revenue ($219.1M vs $177.4M, roughly 1.2× Pacira BioSciences, Inc.). Iridium Communications Inc. runs the higher net margin — 9.9% vs 1.6%, a 8.2% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 1.9%). Over the past eight quarters, Iridium Communications Inc.'s revenue compounded faster (4.4% CAGR vs -0.2%).
Iridium Communications Inc. is a publicly traded American company headquartered in McLean, Virginia, United States. Iridium operates the Iridium satellite constellation, a system of 80 satellites: 66 are active satellites and the remaining fourteen function as in-orbit spares. Iridium Satellites are used for worldwide voice and data communication from handheld satellite phones, satellite messenger communication devices and integrated transceivers, as well as for two-way satellite messaging se...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
IRDM vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $219.1M | $177.4M |
| Net Profit | $21.6M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 23.2% | 3.9% |
| Net Margin | 9.9% | 1.6% |
| Revenue YoY | 1.9% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $219.1M | $177.4M | ||
| Q4 25 | $212.9M | $196.9M | ||
| Q3 25 | $226.9M | $179.5M | ||
| Q2 25 | $216.9M | $181.1M | ||
| Q1 25 | $214.9M | $168.9M | ||
| Q4 24 | $213.0M | $187.3M | ||
| Q3 24 | $212.8M | $168.6M | ||
| Q2 24 | $201.1M | $178.0M |
| Q1 26 | $21.6M | $2.9M | ||
| Q4 25 | $24.9M | — | ||
| Q3 25 | $37.1M | $5.4M | ||
| Q2 25 | $22.0M | $-4.8M | ||
| Q1 25 | $30.4M | $4.8M | ||
| Q4 24 | $36.3M | — | ||
| Q3 24 | $24.4M | $-143.5M | ||
| Q2 24 | $32.3M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | 23.2% | 3.9% | ||
| Q4 25 | 25.9% | 1.2% | ||
| Q3 25 | 30.9% | 3.5% | ||
| Q2 25 | 23.2% | 4.7% | ||
| Q1 25 | 28.1% | 1.2% | ||
| Q4 24 | 24.5% | 13.2% | ||
| Q3 24 | 25.8% | -82.8% | ||
| Q2 24 | 21.7% | 15.9% |
| Q1 26 | 9.9% | 1.6% | ||
| Q4 25 | 11.7% | — | ||
| Q3 25 | 16.4% | 3.0% | ||
| Q2 25 | 10.1% | -2.7% | ||
| Q1 25 | 14.2% | 2.8% | ||
| Q4 24 | 17.1% | — | ||
| Q3 24 | 11.5% | -85.1% | ||
| Q2 24 | 16.1% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.24 | $0.05 | ||
| Q3 25 | $0.35 | $0.12 | ||
| Q2 25 | $0.20 | $-0.11 | ||
| Q1 25 | $0.27 | $0.10 | ||
| Q4 24 | $0.30 | $0.38 | ||
| Q3 24 | $0.21 | $-3.11 | ||
| Q2 24 | $0.27 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $653.9M |
| Total Assets | — | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $96.5M | $238.4M | ||
| Q3 25 | $88.5M | $246.3M | ||
| Q2 25 | $79.3M | $445.9M | ||
| Q1 25 | $50.9M | $493.6M | ||
| Q4 24 | $93.5M | $484.6M | ||
| Q3 24 | $159.6M | $453.8M | ||
| Q2 24 | $63.5M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $1.8B | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $462.6M | $693.1M | ||
| Q3 25 | $450.5M | $727.2M | ||
| Q2 25 | $473.6M | $757.8M | ||
| Q1 25 | $518.4M | $798.5M | ||
| Q4 24 | $576.6M | $778.3M | ||
| Q3 24 | $663.8M | $749.6M | ||
| Q2 24 | $786.7M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.5B | $1.3B | ||
| Q3 25 | $2.6B | $1.3B | ||
| Q2 25 | $2.6B | $1.5B | ||
| Q1 25 | $2.6B | $1.6B | ||
| Q4 24 | $2.7B | $1.6B | ||
| Q3 24 | $2.8B | $1.5B | ||
| Q2 24 | $2.7B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 3.80× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 3.05× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IRDM
| Voice and data | $57.4M | 26% |
| IoT data (2) | $46.0M | 21% |
| Government | $39.5M | 18% |
| Government service revenue (5) | $27.6M | 13% |
| Subscriber equipment | $20.2M | 9% |
| Hosted payload and other data service (4) | $14.8M | 7% |
| Broadband (3) | $12.2M | 6% |
| Commercial | $1.3M | 1% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
